GE Marquette wins awards, signs GPO contract
GE Marquette Medical Systems has garnered two awards from research firm Frost & Sullivan for its use of market research: the Competitive Strategy Award and the Product Line Strategy Award.These awards are based on independent research and analysis of
GE Marquette Medical Systems has garnered two awards from research firm Frost & Sullivan for its use of market research: the Competitive Strategy Award and the Product Line Strategy Award.
These awards are based on independent research and analysis of companies in the healthcare industry. GE Marquette stood out as a sole-source provider of clinical information systems and devices for patient monitoring and cardiology, and the company has been recognized for forming Web-based alliances to keep it competitive, according to Mahpara Qureshi, Frost & Sullivan industry analyst.
GE Marquettes alliances with companies that produce technology complementary to its own products include Draeger, Critikon, NEC Medical Systems, CardioDynamics, Novametrix, Micro Medical, Data Critical, and Aspect Medical Systems. Wisconsin-based GE Marquettes products focus on diagnostic cardiology, patient monitoring, and clinical information systems.
Recently, GE Marquette signed a three-year contract with Consorta Catholic Resource Partners to provide patient monitoring systems and services to its 900 hospitals and clinics around the world.
Under this agreement, GE Marquette will be a preferred provider of patient monitoring solutions, including the Solar family of advanced vital sign monitoring systems, the Eagle model configured monitors, and the portable Dash monitor, which supports continuous patient monitoring during an ambulance or aircraft ride.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
